Meet Pharmidex at KTN 2016
June 14, 2016

Collaboration opportunities in regenerative medicine

Pharmdiex will be attending the Innvoate UK KTN 2016 meeting focused on New Collaboration Opportunities in Regenerative Medicine.

The KTN in collaboration with Innovate UK, Cell and Gene Therapy Catapult, Department of Health and Kings College London are holding an event focussing on new unmet clinical needs, latest developments in regulatory environment and clinical adoption. Following recent developments and the UK’s Regenerative Medicine Expert Group report recommendations, this event will bring together the UK regenerative medicine communities involving industrialists, academics and clinicians from a number of clinical specialities.


The UK is leading the field in the development of cell and gene therapies. The regulatory system now has a number of mechanisms to accelerate the progress of promising therapies including EAMS and the proposed new PRIME scheme. However, practical challenges still exist to the clinical adoption of these new therapies and getting them to patients, including generating sufficient clinical data, achieving reimbursement and embedding therapies in existing or new clinical pathways).


Leading clinicians and experts from a number of organisations will be presenting at this event. Directors and managers from major funding organisations, e.g. Innovate UK, Research Councils, relevant charities will also be invited to support this event.


The main aims of this event are as follows;


  • To discuss challenges affecting clinical adoption of cell and gene-based therapies.
  • Facilitate new clinician/industry collaborations in a number of areas of clinical specialities.
  • Identify barriers to innovation and commercialisation.
  • Review current funding opportunities and identify funding gaps.
  • Provide networking opportunities to identify collaborating partners.
  • Review supporting mechanisms available to accelerate innovation and commercialisation through KTN and partners Innovate UK, Cell and Gene Therapy Catapult organisations.
  • Review current pre-clinical and clinical trials and identify best practice to accelerate regulatory approvals


For more information please see the following link: https://www.eventbrite.co.uk/e/new-collaboration-opportunities-in-regenerative-medicine-tickets-24454460951

March 9, 2026
We are pleased to share that Janette Dalay Robertson will be attending Cell & Gene Therapy 2026 taking place 9–10 March 2026 at Hinxton Hall Conference Centre, Cambridge. This event is a fantastic opportunity to connect with leaders across the cell and gene therapy ecosystem and Janette will be there representing Pharmidex and discussing how our scientific services support drug discovery and development. 🤝 Janette would be delighted to meet with fellow attendees to: • Explore new collaborations • Discuss upcoming research programs • Share how Pharmidex can support innovative therapeutic development If you are attending, feel free to reach out and arrange a meeting during the event. We look forward to engaging conversations and building new partnerships within the cell and gene therapy community!
March 4, 2026
🔬 Unlock deeper insights into how your compound is processed in the body with Pharmidex ’s Drug Metabolism Services. At Pharmidex , we provide specialist drug metabolism studies using advanced UHPLC-high resolution/accurate mass spectrometry to support biotransformation understanding, cross-species metabolite profiling and structural characterisation of metabolites. Our expert team can help you address challenges such as high clearance, identification of metabolically labile sites and potential reactive metabolism liabilities, helping you make data-driven decisions early in the discovery and development process. Learn how our tailored approach can strengthen your metabolic profiling and accelerate your drug development programmes: 🔗 https://www.pharmidex.com/Drug-Metabolism-Service
February 26, 2026
At Pharmidex , we deliver industry-leading Discovery Bioanalysis services grounded in advanced LC-MS technologies to enhance drug discovery and preclinical research, supporting internal studies but also analyzing external samples also Our experienced bioanalytical team works across a wide range of therapeutic modalities, from small molecules and peptides, to oligonucleotides and complex biologics, providing robust, reliable and fit-for-purpose data to accelerate your program and strengthen decision-making during early development. We support both non-GLP and GLP/GCP workflows, method development, validation, and quantitative analysis that align with regulatory needs and industry expectations. Learn more about how our LC-MS capabilities can help you confidently advance your projects: 🔗 https://www.pharmidex.com/Discovery-Bioanalysis
More Posts